Sutar Pharmachemicals Profile
Key Indicators
- Authorised Capital ₹ 2.00 M
- Paid Up Capital ₹ 0.20 M
- Company Age 26 Year, 8 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 2.60 Cr
- Revenue Growth -60.71%
- Profit Growth -73.06%
- Ebitda -78.35%
- Net Worth 1.83%
- Total Assets -13.86%
About Sutar Pharmachemicals
Sutar Pharmachemicals Private Limited (SPPL) is a Private Limited Indian Non-Government Company incorporated in India on 10 June 1998 and has a history of 26 years and eight months. Its registered office is in Khorda, Odisha, India.
The Company is engaged in the Chemicals And Materials Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.00 M and a paid-up capital of Rs 0.20 M.
The company currently has active open charges totaling ₹2.60 Cr.
Sasmita Sutar and Annewaseta Sutar serve as directors at the Company.
Company Details
- Location
Khorda, Odisha, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24243OR1998PTC005344
- Company No.
005344
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
10 Jun 1998
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Cuttack
Industry
Who are the key members and board of directors at Sutar Pharmachemicals?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sasmita Sutar  | Managing Director | 01-Jul-2012 | Current |
Board Members (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Annewaseta Sutar | Director | 02-Mar-2021 | Current |
Financial Performance of Sutar Pharmachemicals.
Sutar Pharmachemicals Private Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 60.71% decrease. The company also saw a substantial fall in profitability, with a 73.06% decrease in profit. The company's net worth moved up by a moderate rise of 1.83%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Sutar Pharmachemicals?
In 2020, Sutar Pharmachemicals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹25.97 M
₹0
Charges Breakdown by Lending Institutions
- State Bank Of India : 2.40 Cr
- Karnataka Bank Ltd. : 0.20 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 18 Sep 2017 | Karnataka Bank Ltd. | ₹2.00 M | Open |
| 24 Dec 2009 | State Bank Of India | ₹2.31 Cr | Open |
| 26 Mar 1999 | State Bank Of India | ₹0.90 M | Open |
How Many Employees Work at Sutar Pharmachemicals?
Unlock and access historical data on people associated with Sutar Pharmachemicals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Sutar Pharmachemicals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sutar Pharmachemicals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
